CD3-Specific Antibodies as Promising Tools to Aim at Immune Tolerance in the Clinic

REFERENCES

• P. Kung, G. Goldstein, E.L. Reinherz, and S.F. Schlossman, Monoclonal antibodies defining distinctive human T cell surface antigens, Science, 206: 347–349, 1979. [CSA]
   PubMed Web of Science ®Google Scholar
• A.B. Cosimi, R.B. Colvin, R.C. Burton, R.H. Rubin, G. Goldstein, P.C. Kung, W.P. Hansen, F.L. Delmonico, and P.S. Russell, Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts, N. Engl. J. Med., 305: 308–314, 1981. [CSA]
   PubMed Web of Science ®Google Scholar
• Ortho Multicenter Transplant Study Group, A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants, N. Engl. J. Med., 313: 337–342, 1985. [CSA]
   PubMed Web of Science ®Google Scholar
• P. Vigeral, N. Chkoff, L. Chatenoud, H. Campos, M. Lacombe, D. Droz, G. Goldstein, J.F. Bach, and H. Kreis, Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent, Transplantation, 41: 730–733, 1986. [CSA]
   PubMed Web of Science ®Google Scholar
• O. Leo, M. Foo, D.H. Sachs, L.E. Samelson, and J.A. Bluestone, Identification of a monoclonal antibody specific for a murine T3 polypeptide, Proc. Natl. Acad. Sci. U. S. A., 84: 1374–1378, 1987. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Clevers, B. Alarcon, T. Wilerman, and C. Terhorst, The T-cell receptor/CD3 complex: a dynamic protein ensemble, Annu. Rev. Immunol., 6: 629–662, 1988. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.P. Van Wauwe, J.R. De Mey, and J.G. Goossens, OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J. Immunol., 124: 2708–2713, 1980. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Hirsch, R.E. Gress, D.H. Pluznik, M. Eckhaus, and J.A. Bluestone, Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells, J. Immunol., 142: 737–743, 1989. [CSA]
   PubMed Web of Science ®Google Scholar
• C. Ferran, K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L.H. Noel, G. Grau, J. Bluestone, J.F. Bach, and L. Chatenoud, Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation, Eur. J. Immunol., 20: 509–515, 1990. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Alegre, P. Vandenabeele, V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman, Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor, Eur. J. Immunol., 20: 707–710, 1990. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, C. Legendre, C. Ferran, J.F. Bach, and H. Kreis, Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome—dosage and kinetics prerequisites, Transplantation, 51: 334–338, 1991. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Abramowicz, L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, L. De Pauw, J. Wybran, P. Kinnaert, E. Dupont, and C. Toussaint, Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients, Transplantation, 47: 606–608, 1989. [CSA]
   PubMed Web of Science ®Google Scholar
• R.A. Van Lier, J.H. Boot, E.R. De Groot, and L.A. Aarden, Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems, Eur. J. Immunol., 17: 1599–1604, 1987. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Hirsch, J.A. Bluestone, L. De Nenno, and R.E. Gress, Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb, Transplantation, 49: 1117–1123, 1990. [CSA]
   PubMed Web of Science ®Google Scholar
• K.J. Parlevliet, I.J. Ten Berge, S.L. Yong, J. Surachno, J.M. Wilmink, and P.T. Schellekens, In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants, J. Clin. Invest., 93: 2519–2525, 1994. [CSA]
   PubMedGoogle Scholar
• L. Chatenoud, J. Primo, and J.F. Bach, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice, J. Immunol., 158: 2947–2954, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, E. Thervet, J. Primo, and J.F. Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc. Natl. Acad. Sci. U. S. A., 91: 123–127, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, CD3-specific antibody-induced active tolerance: from bench to bedside, Nat. Rev. Immunol., 3: 123–132, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C. Hughes, J.A. Wolos, E.H. Giannini, and R. Hirsch, Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody, J. Immunol., 153: 3319–3325, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• K.C. Herold, J.A. Bluestone, A.G. Montag, A. Parihar, A. Wiegner, R.E. Gress, and R. Hirsch, Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody, Diabetes, 41: 385–391, 1992. [CSA]
   PubMed Web of Science ®Google Scholar
• B.D. Johnson, C. Mccabe, C.A. Hanke, and R.L. Truitt, Use of anti-CD3 epsilon F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation, J. Immunol., 154: 5542–5554, 1995. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Bolt, E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S.D. Gorman, M. Clark, and H. Waldmann, The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties, Eur. J. Immunol., 23: 403–411, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• M.L. Alegre, L.J. Peterson, D. Xu, H.A. Sattar, D.R. Jeyarajah, K. Kowalkowski, J.R. Thistlethwaite, R.A. Zivin, L. Jolliffe, and J.A. Bluestone, A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo, Transplantation, 57: 1537–1543, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• J.A. Smith, Q. Tang, and J.A. Bluestone, Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets, J. Immunol., 160: 4841–4849, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• J.A. Smith, J.Y. Tso, M.R. Clark, M.S. Cole, and J.A. Bluestone, Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy, J. Exp. Med., 185: 1413–1422, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, M.F. Baudrihaye, H. Kreis, G. Goldstein, J. Schindler, and J.F. Bach, Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody, Eur. J. Immunol., 12: 979–982, 1982. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, M.F. Baudrihaye, N. Chkoff, H. Kreis, G. Goldstein, and J.F. Bach, Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3, J. Immunol., 137: 830–838, 1986. [CSA]
   PubMed Web of Science ®Google Scholar
• K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian Ruiz, L. Taylor, D. Donaldson, S.E. Gitelman, D.M. Harlan, D. Xu, R.A. Zivin, and J.A. Bluestone, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med., 346:1692–1698, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B. Keymeulen, E. Vandemeulebroucke, A.G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, L. Schandene, L. Crenier, C. De Block, J.M. Seigneurin, P. De Pauw, D. Pierard, I. Weets, P. Rebello, P. Bird, E. Berrie, M. Frewin, H. Waldmann, J.F. Bach, D. Pipeleers, and L. Chatenoud, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N. Engl. J. Med., 352: 2598–2608, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Hirsch, M. Eckhaus, J.R. Auchincloss H, D.H. Sachs, and J.A. Bluestone, Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses, J. Immunol., 140: 3766–3772, 1988. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud, E. Thervet, J. Primo, and J.F. Bach, Rémission de la maladie établie chez la souris NOD diabétique par l'anticorps monoclonal anti-CD3, C. R. Acad. Sci. III, 315: 225–228, 1992. [CSA]
   PubMedGoogle Scholar
• J.T. Wong and R.B. Colvin, Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis, Clin. Immunol. Immunopathol., 58: 236–250, 1991. [CSA], [CROSSREF]
   Google Scholar
• S. Wesselborg, O. Janssen, and D. Kabelitz, Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells, J. Immunol., 150: 4338–4345, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Chatenoud and J.F. Bach, Antigenic modulation: a major mechanism of antibody action, Immunol. Today, 5: 20–25, 1984. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• A.P. Monaco, M.L. Wood, and P.S. Russell, Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum, Ann. N. Y. Acad. Sci., 129: 190–209, 1966. [CSA]
   Web of Science ®Google Scholar
• M.L. Wood, A.P. Monaco, J.J. Gozzo, and A. Liegeois, Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing, Transplant. Proc., 3: 676–679, 1971. [CSA]
   Google Scholar
• J.M. Thomas, F.M. Carver, M.B. Foil, W.R. Hall, C. Adams, and G.B. Fahrenbruch, Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys, Transplantation, 36: 104–106, 1983. [CSA]
   Google Scholar
• T. Maki, T. Ichikawa, R. Blanco, and J. Porter, Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum, Proc. Natl. Acad. Sci. U. S. A., 89: 3434–3438, 1992. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.J. Benjamin, S.P. Cobbold, M.R. Clark, and H. Waldmann, Tolerance to rat monoclonal antibodies. Implications for serotherapy, J. Exp. Med., 163: 1539–1552, 1986. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N.L. Gutstein, W.E. Seaman, J.H. Scott, and D. Wofsy, Induction of immune tolerance by administration of monoclonal antibody to L3T4, J. Immunol., 137: 1127–1132, 1986. [CSA]
   PubMedGoogle Scholar
• N.L. Gutstein and D. Wofsy, Administration of F(ab′)2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells, J. Immunol., 137: 3414–3419, 1986. [CSA]
   Google Scholar
• J. Goronzy, C.M. Weyand, and C.G. Fathman, Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4, J. Exp. Med., 164: 911–925, 1986. [CSA], [CROSSREF]
   Google Scholar
• R.J. Benjamin and H. Waldmann, Induction of tolerance by monoclonal antibody therapy, Nature, 320: 449–451, 1986. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.J. Benjamin, S.X. Qin, M.P. Wise, S.P. Cobbold, and H. Waldmann, Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination, Eur. J. Immunol., 18: 1079–1088, 1988. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Wofsy, D.C. Mayes, J. Woodcock, and W.E. Seaman, Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice, J. Immunol., 135: 1698–1701, 1985. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Winsor-Hines, C. Merrill, M. O'Mahony, P.E. Rao, S.P. Cobbold, H. Waldmann, D.J. Ringler, and P.D. Ponath, Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody, J. Immunol., 173: 4715–4723, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• J.A. Shizuru, A.K. Gregory, C.T. Chao, and C.G. Fathman, Islet allograft survival after a single course of treatment of recipient with antibody to L3T4, Science, 237: 278–280, 1987. [CSA]
   PubMedGoogle Scholar
• J.A. Shizuru, K.B. Seydel, T.F. Flavin, A.P. Wu, C.C. Kong, E.G. Hoyt, N. Fujimoto, M.E. Billingham, V.A. Starnes, and C.G. Fathman, Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy, Transplantation, 50: 366–373, 1990. [CSA]
   Google Scholar
• J.A. Shizuru, C. Taylor-edwards, B.A. Banks, A.K. Gregory, and C.G. Fathman, Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes, Science, 240: 659–662, 1988. [CSA]
   PubMed Web of Science ®Google Scholar
• J.C. Madsen, W.N. Peugh, K.J. Wood, and P.J. Morris, The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts, Transplantation, 44: 849–852, 1987. [CSA]
   Google Scholar
• A. Siegling, M. Lehmann, H. Riedel, C. Platzer, J. Brock, F. Emmrich, and H.D. Volk, A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts, Transplantation, 57: 464–467, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• T.C. Pearson, J.C. Madsen, C.P. Larsen, P.J. Morris, and K.J. Wood, Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody, Transplantation, 54: 475–483, 1992. [CSA]
   PubMed Web of Science ®Google Scholar
• S.X. Qin, S. Cobbold, R. Benjamin, and H. Waldmann, Induction of classical transplantation tolerance in the adult, J. Exp. Med., 169: 779–794, 1989. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• S. Qin, S.P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann, “Infectious” transplantation tolerance, Science, 259: 974–977, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Wofsy and W.E. Seaman, Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4, J. Immunol., 138: 3247–3253, 1987. [CSA]
   PubMed Web of Science ®Google Scholar
• L. Makhlouf, S.T. Grey, V. Dong, E. Csizmadia, M.B. Arvelo, H. Auchincloss, Jr., C. Ferran, and M.H. Sayegh, Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice, Transplantation, 77: 990–997, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C.P. Larsen, E.T. Elwood, D.Z. Alexander, S.C. Ritchie, R. Hendrix, C. Tuckerburden, H.R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K.J. Winn, and T.C. Pearson, Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways, Nature, 381: 434–438, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.J. Lenschow, Y. Zeng, J.R. Thistlethwaite, A. Montag, W. Brady, M.G. Gibson, P.S. Linsley, and J.A. Bluestone, Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg, Science, 257: 789–792, 1992. [CSA]
   PubMed Web of Science ®Google Scholar
• A.D. Kirk, L.C. Burkly, D.S. Batty, R.E. Baumgartner, J.D. Berning, K. Buchanan, J.R. Fechner Jh, R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, D.K. Tadaki, C.N. Tenhoor, L. White, S.J. Knechtle, and D.M. Harlan, reatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates, Nat. Med., 5: 686–693, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.A. Quezada, L.Z. Jarvinen, E.F. Lind, and R.J. Noelle, CD40/CD154 interactions at the interface of tolerance and immunity, Annu. Rev. Immunol., 22: 307–328, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.H. Adler and L.A. Turka, Immunotherapy as a means to induce transplantation tolerance, Curr. Opin. Immunol., 14: 660–665, 2002. [CSA], [CROSSREF]
   Google Scholar
• T. Wekerle, J. Kurtz, S. Bigenzahn, Y. Takeuchi, and M. Sykes, Mechanisms of transplant tolerance induction using costimulatory blockade, Curr. Opin. Immunol., 14: 592–600, 2002. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• M.R. Nicolls, G.G. Aversa, N.W. Pearce, A. P6spinelli, M.F. Berger, K.E. Gurley, and B.M. Hall, Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody, Transplantation, 55: 459–468, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• K.M. Plain, J. Chen, S. Merten, X.Y. He, and B.M. Hall, Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy, Transplantation, 67: 605–613, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.M. Thomas, D.M. Neville, J.L. Contreras, D.E. Eckhoff, G. Meng, A.L. Lobashevsky, P.X. Wang, Z.Q. Huang, K.M. Verbanac, C.E. Haisch, and F.T. Thomas, Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts, Transplantation, 64: 124–135, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• M.M. Hamawy and S.J. Knechtle, Strategies for tolerance induction in nonhuman primates, Curr. Opin. Immunol., 10: 513–517, 1998. [CSA], [CROSSREF]
   Google Scholar
• F.T. Thomas, C. Ricordi, J.L. Contreras, W.J. Hubbard, X.L. Jiang, D.E. Eckhoff, S. Cartner, G. Bilbao, J.R. Neville Dm, and J.M. Thomas, Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression, Transplantation, 67: 846–854, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Makino, K. Kunimoto, Y. Muraoka, Y. Mizushima, K. Katagiri, and Y. Tochino, Breeding of a non-obese, diabetic strain of mice, Exp. Anim., 29: 1–13, 1980. [CSA]
   PubMedGoogle Scholar
• J.F. Bach, Insulin-dependent diabetes mellitus as an autoimmune disease, Endocrine. Rev., 15: 516–542, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L.K. Shoda, D.L. Young, S. Ramanujan, C.C. Whiting, M.A. Atkinson, J.A. Bluestone, G.S. Eisenbarth, D. Mathis, A.A. Rossini, S.E. Campbell, R. Kahn, and H.T. Kreuwel, A comprehensive review of interventions in the NOD mouse and implications for translation, Immunity, 23: 115–126, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.P. Kohm, J.S. Williams, A.L. Bickford, J.S. McMahon, L. Chatenoud, J.F. Bach, J.A. Bluestone, and S.D. Miller, Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis, J. Immunol., 174: 4525–4534, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• B.R. Ludviksson, R.O. Ehrhardt, and W. Strober, TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice, J. Immunol., 159: 3622–3628, 1997. [CSA]
   Google Scholar
• M.B. Oldstone, M. Nerenberg, P. Southern, J. Price, and H. Lewicki, Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response, Cell, 65: 319–331, 1991. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.G. Von Herrath, J. Dockter, and M.B. Oldstone, How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model, Immunity, 1: 231–242, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.G. Von Herrath, B. Coon, T. Wolfe, and L. Chatenoud, Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance, J. Immunol., 168: 933–941, 2002. [CSA]
   PubMedGoogle Scholar
• M. Belghith, J.A. Bluestone, S. Barriot, J. Megret, J.F. Bach, and L. Chatenoud, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes, Nat. Med., 9: 1202–1208, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.F. Bach and L. Chatenoud, Tolerance to islet autoantigens and type I diabetes Annu. Rev. Immunol., 19: 131–161, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.A. Bluestone and A.K. Abbas, Natural versus adaptive regulatory T cells, Nat. Rev. Immunol., 3: 253–257, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Sakaguchi, Regulatory T cells: Key controllers of immunologic self-tolerance, Cell, 101: 455–458, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B. Salomon, D.J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J.A. Bluestone, B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes, Immunity, 12: 431–440, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.B. Cosimi, R.C. Burton, R.B. Colvin, G. Goldstein, F.L. Delmonico, M.P. Laquaglia, N. Tolkoff-rubin, R.H. Rubin, J.T. Herrin, and P.S. Russell, Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation, 32: 535–539, 1981. [CSA]
   PubMed Web of Science ®Google Scholar
• P.J. Friend, G. Hale, L. Chatenoud, P. Rebello, J. Bradley, S. Thiru, J.M. Phillips, and H. Waldmann, Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection, Transplantation, 68: 1632–1637, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• E.S. Woodle, D. Xu, R.A. Zivin, J. Auger, J. Charette, R. O'laughlin, D. Peace, L.K. Jollife, T. Haverty, J.A. Bluestone, and J.R. Thistlethwaite Jr, Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection, Transplantation, 68: 608–616, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B.J. Hering, R. Kandaswamy, J.V. Harmon, J.D. Ansite, S.M. Clemmings, T. Sakai, S. Paraskevas, P.M. Eckman, J. Sageshima, M. Nakano, T. Sawada, I. Matsumoto, H.J. Zhang, D.E. Sutherland, and J.A. Bluestone, Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody, Am. J. Transplant, 4: 390–401, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T.O. Utset, J.A. Auger, D. Peace, R.A. Zivin, D. Xu, L. Jolliffe, M.L. Alegre, J.A. Bluestone, and M.R. Clark, Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial, J. Rheumatol., 29: 1907–1913, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• K.C. Herold, S.E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D.M. Harlan, and J.A. Bluestone, A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes, Diabetes, 54: 1763–1769, 2005. [CSA]
   PubMed Web of Science ®Google Scholar